EVA pharma, as a revolutionary pharmaceutical company, is research oriented and science driven. It continues to raise the standards of healthcare, through offering premium quality products. Thiotacid is one of the innovative products that EVA pharma has introduced in Egypt.
Thiotacid was introduced to the world of diabetes as a new pathogenetic approach to manage diabetic neuropathy. Being an international company, EVA pharma made this unique product available in Africa, America & Asia to help as many patients as possible. Despite the massive amount of data & clinical evidence that supports the use of Thiotacid in diabetic patients; most of these trials were conducted on European patients. And, since EVA pharma is patients’ oriented and its primary focus is the Egyptian patient, EVA pharma was eager to prove the efficacy and safety of Thiotacid in Egyptian patients. Hence, came the need to conduct a national Egyptian clinical study to evaluate the role of Thiotacid in our local environment. EVA pharma was honored to support the conduction of the clinical study “Oral alpha lipoic acid as an adjunctive treatment for symptomatic diabetic peripheral neuropathy” in Egypt and; 200 Egyptian patients were enrolled in the study.
The study results will be presented in the EASD conference 2017, which is the biggest European conference for Endocrinology. EVA pharma is keen to reveal such valuable scientific findings to the Egyptian doctors before being presented to the international societies. And; the objective of our meeting today is to share with the respected specialized doctors the results of this study. The study details: Objective: To assess the efficacy of oral intake of ALA (Thiotacid®) 600 mg twice daily in the treatment of type 2 diabetic patients with Diabetic Peripheral Neuropathy. Chief Investigator: Prof. Mamdouh Elnahas, Professor of Internal Medicine and Diabetes, Mansoura University. Location: Mansoura University hospital, outpatient clinics Patients: 200 type II diabetic patients suffering from peripheral diabetic neuropathy. Follow up and assessment: Baseline. Then 1 , 3 and 6 months. The endpoints: Neurological Symptom Score “NSS”, Neurological Disability Score “NDS” and Vibration perception thresholds “VPT”. Conclusion: Thiotacid® showed very highly significant improvement compared to placebo in management of peripheral neuropathy in diabetes mellitus type II patients in terms of NSS, NDS and VPT over the course of 6 months.